Rebleeds Common Post-Capsule Endoscopy for Obscure GI Bleeds

This article originally appeared here.
Share this content:
Rebleeds Common Post-Capsule Endoscopy for Obscure GI Bleeds
Rebleeds Common Post-Capsule Endoscopy for Obscure GI Bleeds

TUESDAY, Dec. 30, 2014 (HealthDay News) -- Nearly one-third of patients who undergo capsule endoscopy (CE) for obscure gastrointestinal bleeding (OGIB) have rebleeding a year or more later, according to research published online Dec. 15 in the Journal of Digestive Diseases.

Wei Tan, of the Shanghai Jiaotong University School of Medicine, and colleagues conducted a retrospective study of 372 consecutive patients who underwent CE for OGIB from June 2002 to January 2012. Long-term outcomes and risk factors associated with rebleeding were examined.

The researchers found that rebleeding occurred in 28.6 percent of patients at 12 to 112 months after CE (median, 48 months). According to multivariate analysis, CE positive findings (hazard ratio [HR], 3.393; 95 percent confidence interval [CI], 1.931 to 5.963); anticoagulants, antiplatelet, or nonsteroidal anti-inflammatory drug use after CE (HR, 2.851; 95 percent CI, 1.433 to 5.674); nonspecific treatments (HR, 2.5; 95 percent CI, 1.625 to 3.848); age ≥60 years (HR, 2.473; 95 percent CI, 1.576 to 3.881); and hemoglobin levels ≤7g/dL before CE (HR, 2.01; 95 percent CI, 1.261 to 3.206) were independently associated with risk of rebleeding. In univariate analysis, chronic hepatitis was independently associated with rebleeding in patients with negative findings on CE.

"Further investigation and close follow-up in patients with OGIB and CE negative patients is necessary," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

Doctors Remove Contact Lens Embedded in Eyelid for Years

Doctors Remove Contact Lens Embedded in Eyelid for ...

Lens was encapsulated within the upper eyelid soft tissue since childhood eye trauma

CDC: Brucellosis in Dogs Remains a Public Health Risk

CDC: Brucellosis in Dogs Remains a Public Health ...

Infection is under-recognized, may remain a threat without stronger intervention measures

is free, fast, and customized just for you!




Already a member?

Sign In Now »